Analysts expect Neuphoria Therapeutics Inc. to report revenue of 6.46 M for 2021, against a range of 6.15 M to 6.78 M. The most recent reported year, 2025, came in at 15.65 M, a 41.3% beat against the 11.08 M consensus.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | - | 183,700.00 | 943,160.00 | 958,610.00 | 15.65 M | - | |||
| High Estimate | 6.78 M | -676,756.47 | 815,508.45 | 1.78 M | 11.57 M | 0.00 | |||
| Low Estimate | 6.15 M | -735,463.89 | 694,133.25 | 1.57 M | 10.58 M | 0.00 | |||
| Consensus Estimate | 6.46 M | -706,110.18 | 754,820.85 | 1.68 M | 11.08 M | 0.00 |
Analysts expect Neuphoria Therapeutics Inc. to report earnings per share of -3.95 for 2026, against a range of -4.10 to -3.80. The most recent reported year, 2025, came in at -0.23, a 157.5% miss against the 0.40 consensus.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -15.69 | -30.10 | -29.64 | -21.62 | -0.23 | - | - | ||
| High Estimate | -15.54 | -28.98 | -25.28 | -26.66 | 0.44 | -3.80 | -2.29 | ||
| Low Estimate | -17.70 | -32.26 | -29.80 | -32.36 | 0.36 | -4.10 | -2.79 | ||
| Consensus Estimate | -16.62 | -30.62 | -27.54 | -29.51 | 0.40 | -3.95 | -2.54 |